Loading
Hematopoietic Stem Cell Transplantation / Prenatal Screening and Diagnostics / Hemoglobinopathies and Related Disorders · Journal article
Current Opinion in Hematology · September 8, 2026
A consensus or society position rather than new primary data.
This is a narrative review of recent advances in allogeneic and autologous stem cell transplantation for sickle cell disease, positioning matched sibling HSCT as the clinical benchmark while describing emerging haploidentical and gene-edited approaches. The authors identify a convergent challenge across curative therapies: establishing durable healthy hematopoiesis with acceptable toxicity, and note that prenatal and in vivo approaches remain preclinical.
Narrative review. Patients with sickle cell disease undergoing hematopoietic stem cell transplantation or gene-modified stem cell transplantation.
Matched sibling HSCT remains clinical benchmark with age- and regimen-dependent trade-offs between engraftment, graft-versus-host disease and toxicity Haploidentical platforms using posttransplant cyclophosphamide, thiotepa or intensified low-dose irradiation have widened donor access Autologous CRISPR-edited and lentiviral grafts can nearly eliminate severe vaso-occlusive events but require myeloablative conditioning and individualized manufacture
No quantitative efficacy or safety data reported for any approach; review does not provide effect sizes, event rates or comparative outcomes Prenatal and in vivo strategies explicitly noted as preclinical with insufficient safety data for clinical use
Clinicians should recognize that matched sibling HSCT remains the established standard but haploidentical approaches and gene-modified autologous strategies offer expanding therapeutic options with distinct risk-benefit profiles. The identified barriers to durable engraftment and safety should inform patient selection and counselling.
This is a narrative review synthesizing recent advances in HSCT and gene-modified stem cell transplantation for sickle cell disease, offering expert perspective on current clinical benchmarks and emerging approaches rather than reporting new primary evidence.
As stated by the source record.
Clinicians should recognize that matched sibling HSCT remains the established standard but haploidentical approaches and gene-modified autologous strategies offer expanding therapeutic options with distinct risk-benefit profiles. The identified barriers to durable engraftment and safety should inform patient selection and counselling.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Purpose of review To review advances from the past 18 months in allogeneic hematopoietic stem cell transplantation (HSCT) and autologous gene-modified stem cell transplantation for sickle cell disease (SCD), and to relate these developments to stem cell biology, conditioning and emerging prenatal strategies. Recent findings Matched sibling HSCT remains the clinical benchmark, but recent studies show age- and regimen-dependent trade-offs between durable engraftment, graft-versus-host disease and toxicity. Haploidentical platforms using posttransplant cyclophosphamide, thiotepa or intensified low-dose irradiation have widened donor access, although infection, graft failure and chronic graft-versus-host disease remain important. Autologous CRISPR-edited and lentiviral grafts can nearly eliminate severe vaso-occlusive events, but still require stem cell collection, individualized manufacture and myeloablative conditioning. New work identifies inflammation, lineage skewing, reduced GATA1 and premature senescence as determinants of sickle stem cell fitness, while culture-sparing editing and antibody-directed conditioning offer routes to safer transplantation. Summary Curative SCD therapies are converging on the same challenge: establishing durable healthy hematopoiesis with acceptable toxicity. Progress will depend on graft quality, safer niche creation, patient-centred outcomes and equitable delivery. In vivo and prenatal approaches remain preclinical and require a substantially higher maternal-foetal safety threshold.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.